February 5, 2025
Annovis Bio, Inc. Announces Closing of $21 Million Public Offering
MALVERN, PA, Feb. 04, 2025 (GLOBE NEWSWIRE) — via IBN – Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a…
Pharmaceuticals, Biotechnology and Life Sciences
Category: news
February 5, 2025
Jasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference
REDWOOD CITY, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company…
February 3, 2025
hVIVO, Inhalon Biopharma sign RSV human challenge trial contract
hVIVO has signed a contract with Inhalon Biopharma to assess its inhaled IN-002 antiviral candidate (“IN-002”) using the hVIVO Respiratory Syncytial Virus (RSV) Human Challenge Model.
February 3, 2025
Roche gets FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for ENHERTU
Roche announced Monday that the U.S. Food and Drug Administration (FDA) has approved a label expansion for the PATHWAY® anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody* to identify patients with HR-positive, HER2-ultralow metastatic breast cancer who may be eligible for treatment with ENHERTU®.
February 1, 2025
Annovis Bio, Inc. Announces Proposed Public Offering
MALVERN, Pa., Jan. 31, 2025 (GLOBE NEWSWIRE) — via IBN – Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”),…
February 1, 2025
Evaxion announces closing of $10.8 million public offering
COPENHAGEN, Denmark, January 31, 2025 – Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™…
February 1, 2025
Oculis updates share capital for its existing at-the-market offering program
ZUG, Switzerland, Jan. 31, 2025 (GLOBE NEWSWIRE) — Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a…
February 1, 2025
Bavarian Nordic – Completion of Share Buy-Back Program
COPENHAGEN, Denmark, January 31, 2025 – Bavarian Nordic A/S (OMX: BAVA) announces that the share buy-back program, which was announced…
February 1, 2025
Correction: GUERBET : Financial agenda for 2025
CORRECTION – Financial agenda for 2025 Villepinte, 13 janvier 2025: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and…
February 1, 2025
Intelligent Bio Solutions Expands Global Reach with Multilingual Drug Screening System Upgrade
Multilingual upgrade will make INBS’ Drug Screening System accessible to over 4 billion users worldwide, including users across the Americas,…